Incepta brings vaccine for cervical cancer

Incepta Vaccine Ltd, the country's first vaccine manufacturing company, has launched cervical cancer vaccine Papilovax in Bangladesh.

Papilovax vaccine protects against cervical cancer by preventing the HPV virus responsible for cervical cancer, Incepta said in a statement yesterday.

Cervical cancer is the second leading cause of female cancer deaths in Bangladesh. The main cause of death in this cancer is ignorance and years of neglect, according to the statement.

Every year more than 10,000 women die of cervical cancer in the country and more than 5 crore women are at risk of it.

By giving this vaccine to all healthy women from 9 to 45 years, Bangladesh will go a long way in eradicating cervical cancer. This vaccine will help meet the long-standing demand in the country.

Papilovax is also marketed in modern pre-filled syringes. It should be noted here that the full dose in pre-filled syringes is manufactured in aseptic environment and marketed at controlled temperature in fully sterile packaging.